Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases

Maria K. Skytthe,¹ Jonas Heilskov Graversen,^1,* and Søren K. Moestrup, Int J Mol Sci. 2020 Aug; 21(15): 5497.

In conclusion, the specific targeting of CD163⁺ macrophages has been demonstrated to be a promising drug delivery strategy for handling inflammatory and malignant disease, contributing to the current pharmaceutical therapies.

(nih.gov)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432735/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432735/pdf/ijms-21-05497.pdf